Houston, TXNCT07617337Now EnrollingIRB Ready

ALK Positive Non-small Cell Lung Cancer Clinical Trial in Houston, TX

Access cutting-edge alk positive non-small cell lung cancer treatment through this phase 1 clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by Chugai Pharmaceutical

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access alk positive non-small cell lung cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related alk positive non-small cell lung cancer treatment provided free

Apply for This Houston Location

Check if you qualify for this alk positive non-small cell lung cancer clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This ALK Positive Non-small Cell Lung Cancer Study in Houston

This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as single agent and in combination with lorlatinib in patients with ALK positive non-small cell lung cancer.

Sponsor: Chugai Pharmaceutical

Who Can Participate

Inclusion Criteria

Age ≥ 18 years (or ≥ 20 years if required by local regulation) at time of signing Informed Consent Form
Previously treated with at least one ALK-TKI regardless of prior chemotherapy treatment (Patients who have received only crizotinib as prior ALK-TKI treatment will not be allowed.)
Histologically or cytologically (excluding sputum cytology) proven diagnosis of locally advanced unresectable or metastatic ALK-positive NSCLC, who have experienced disease progression during or following their most recent systemic therapy or have discontinued the therapy due to unacceptable toxicity
Measurable disease per RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Ability and willingness to take oral medication(s)
Adequate organ function and bone marrow reserve

Exclusion Criteria

Prior toxicities from anti-cancer therapy which have not resolved to Grade ≤ 1 per NCI CTCAE v5.0 excluding alopecia, vitiligo, or endocrinopathies manageable with replacement therapy
Symptomatic, active CNS metastases or untreated CNS metastases requiring any definitive therapy.
Severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or renal disease, or active infection), or with a history or complication of interstitial lung disease
Significant cardiovascular disease
Inadequately controlled hypertension
(Part B only) Patients with prior lorlatinib treatment who experienced serious lorlatinib-related toxicities, or who experienced toxicities considered inappropriate for study participation at the discretion of the Investigator

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT07617337) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

ALK Positive Non-small Cell Lung Cancer Treatment Options in Houston, TX

If you're searching for alk positive non-small cell lung cancer treatment options in Houston, TX, this clinical trial (NCT07617337) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced alk positive non-small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alk positive non-small cell lung cancer clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Houston, TX

See all lung cancer clinical trials recruiting in Houston — not just this study.

Browse Lung Cancer Trials in Houston →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSmall Cell Lung Cancer TrialsNon-Small Cell Lung Cancer TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX